Table 3.
Male patients’ characteristics
| ABVD group | BEACOPP group | p value | |
|---|---|---|---|
| Number of patients | 27 | 20 (16e, 4b) | NA |
| Median age in years at diagnosis (range) | 28 (range 20–39) | 25.5 (range 16–38) | p = 0.054 |
| Stage of disease prior to treatment | |||
| I | 4 (14.8 %) | 2a (10.0 %) | NA |
| II | 23 (85.2 %) | 1a (5.0 %) | NA |
| III | 0 (0 %) | 7 (35.0 %) | NA |
| IV | 0 (0 %) | 10 (50.0 %) | NA |
| A/B | 24 (88.9 %)/3 (11.1 %) | 11 (55.0 %)/9 (45.0 %) | p = 0.016 |
| X | 6 (22.2 %) | 9 (45.0 %) | p = 0.122 |
| E | 1 (3.7 %) | 2 (10.0 %) | p = 0.563 |
| Median number of cycles (range) | 4 (1–6) | 8 (4–8) | NA |
| CR/PR after chemotherapy | 3 (11.1 %)/24 (88.9 %) | 11 (55.0 %)/9 (45.0 %) | p = 0.003 |
| Irradiation of the scrotum | 1 (3.7 %) | 0 (0 %) | p = 1.000 |
| Number of patients receiving at least 1 cycle of eBEACOPP | 0 (0 %) | 16 (80.0 %) | NA |
| Number of patients with children before treatment | 10 (37.0 %) | 8 (40.0 %) | p = 1.000 |
| Sperm cryoconservation prior treatment | 19 (70.4 %) | 18 (90.0 %) | p = 0.154 |
| Number of patients achieving pregnancy after therapy/in vitro fertilizationb | 10 (37.0 %)/1 (10.0 %) | 6 (30.0 %)/5 (83.3 %) | p = 0.753/p = 0.008 |
| Number of patients attempting conception post-treatment | 19 (70.4 %) | 18 (90.0 %) | p = 0.154 |
| Number of patients having children after therapyc | 10 (52.6 %) | 6 (33.3 %) | p = 0.554 |
| Aging male symptoms/mean score | 13 (48.1 %)/4.60 | 10 (50.0 %)/3.80 | p = 1.000 |
Italic values indicate statistical significance
A without constitutional symptoms, B with constitutional symptoms, X bulky disease, E extranodal involvement, CR complete remission, PR partial remission, NA not applicable, e escalated, b basal
aAll patients with stage I and II in BEACOPP group were treated with regular-dose BEACOPP
bNumber of artificially inseminated or in vitro fertilized pregnancies among achieved pregnancies after treatment
cPercentage of patients attempting conception post-treatment